Manage Your Liver

Why is the hepatitis C virus (HCV) so difficult to kill?


The hepatitis C virus (HCV) infects millions of people worldwide. Patients are desperate for an effective treatment but medical professionals and the pharmaceutical industry have yet come up with the ideal one. There are two main reasons why HCV is so hard to kill.


First, HCV knocks out the host’s innate immunity. By constant mutation, HCV may be able to escape detection and elimination by the host’s immune system. [1] Therefore, it is almost impossible for the host to kill the virus without external help.


Second, HCV is highly mutable. HCV is an RNA virus and lacks proofreading ability as it replicates, therefore dozens of mutated forms arise. Even within an individual, slightly different genetic versions of HCV are present. According to WHO, there are at least 11 HCV genotypes identified throughout the world. The genotype is the strain of the virus to which patients were exposed when they were infected. [1]


The genotype generally does not affect the progression of liver diseases. However, it is of great clinical importance; different genotypes vary in their responsiveness to HCV treatments. For example, compared with genotype 1, patients with genotypes 2 and 3 are more likely to achieve a sustained virological response to interferon/ribavirin therapy. In addition, therapy duration also varies among different genotypes. Patients with genotypes 2 or 3 generally are treated with combination therapy for only 24 weeks, while patients with genotype 1 usually receive treatment for 48 weeks. [2]


Traditionally, combination therapy with interferon/ribavirin is recommended for HCV patients. Interferons do not directly kill the virus; instead they boost the immune system response to attack the virus. The success rate for such therapy is very low and often comes with unbearable side effects such as fever, headache and other flu-like symptoms. [3]


In recent years, new medications for HCV were developed. One of the most promising is Harvoni, a direct-acting antiviral (DAA) medication. Unlike interferon, DAAs directly inhibit the ability of HCV to replicate. Harvoni is a combination of two DAAs where one interferes with the reproduction of the virus’s genetic material, while the other interferes with a protein needed to complete the virus life cycle in the liver cell.


Although Harvoni claims to have high success rates in clinical studies, not many patients can afford it due to its extremely high cost. Moreover, a person could get infected again even after successful treatment. [4]


Despite the introduction of new drugs, treatment options for hepatitis C patients are still limited. If patients are unable to receive antiviral treatment due to genotype or financial reasons, or have tried and failed, they should shift their treatment focus to protecting liver function and reducing inflammation (ALT).

  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
About 2.7 million persons in the United States are infected with hepatitis C virus in their blood. The majority of these individuals remain asymptomatic for many years following the initial infection, and many people can even live their whole life with hepatitis C virus in their body without knowing they are infected. On the other hand, some carriers will develop chronic hepatitis C, meaning that the virus in their body attacks the liver, causing liver damage with elevated alan
Since the introduction of direct-acting antiviral (DAA) therapy, treatment for hepatitis C (HCV) was revolutionized, as patient outcomes are improved with fewer side effects and high cure rate. However, there is significant debate in the society based on studies that suggest HCV cure does not eliminate risk for hepatocellular carcinoma (HCC) or liver cancer. Other research suggests the possibility of increased risk of developing liver cancer during and after DAA treatment in patients with hep
Hit Questions
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
ALT (Alanine Aminotransferase / SGPT) is a type of enzyme found in liver cells. When the liver cells are functioning normally, the ALT enzymes should be contained within the liver cells.    You can imagine each liver cells as a balloon, and the ALT enzymes are the air inside the balloon. When the balloon is damaged, the air will be released. And when the liver cells is damaged, ALT enzymes are released into the bloodstream, therefore we are able to find out the l
YHK Liver Therapy
Your Liver

starts here.
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us